WO2008109871A8 - Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof - Google Patents

Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof Download PDF

Info

Publication number
WO2008109871A8
WO2008109871A8 PCT/US2008/056316 US2008056316W WO2008109871A8 WO 2008109871 A8 WO2008109871 A8 WO 2008109871A8 US 2008056316 W US2008056316 W US 2008056316W WO 2008109871 A8 WO2008109871 A8 WO 2008109871A8
Authority
WO
WIPO (PCT)
Prior art keywords
pcsk9
crystal structure
proprotein convertase
coordinates
studying
Prior art date
Application number
PCT/US2008/056316
Other languages
French (fr)
Other versions
WO2008109871A2 (en
WO2008109871A3 (en
Inventor
Glen Spraggon
Eric N Hampton
Original Assignee
Irm Llc
Glen Spraggon
Eric N Hampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Glen Spraggon, Eric N Hampton filed Critical Irm Llc
Publication of WO2008109871A2 publication Critical patent/WO2008109871A2/en
Publication of WO2008109871A3 publication Critical patent/WO2008109871A3/en
Publication of WO2008109871A8 publication Critical patent/WO2008109871A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a crystallized PCSK9 molecule. The three-dimensional coordinates of the crystal structure of PCSK9 are obtained by X-ray diffraction. The coordinates can be used for studying the PCSK9 structure and designing, screening and developing compounds that modulate PCSK9 activity.
PCT/US2008/056316 2007-03-08 2008-03-07 Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof WO2008109871A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89382807P 2007-03-08 2007-03-08
US60/893,828 2007-03-08

Publications (3)

Publication Number Publication Date
WO2008109871A2 WO2008109871A2 (en) 2008-09-12
WO2008109871A3 WO2008109871A3 (en) 2009-02-26
WO2008109871A8 true WO2008109871A8 (en) 2009-07-09

Family

ID=39739149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/056316 WO2008109871A2 (en) 2007-03-08 2008-03-07 Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109871A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563698B2 (en) 2007-08-23 2013-10-22 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3169710A1 (en) * 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226243A2 (en) * 1999-10-22 2002-07-31 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
EP1471152A1 (en) * 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563698B2 (en) 2007-08-23 2013-10-22 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8829165B2 (en) 2007-08-23 2014-09-09 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871913B2 (en) 2007-08-23 2014-10-28 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871914B2 (en) 2007-08-23 2014-10-28 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883983B2 (en) 2007-08-23 2014-11-11 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9493576B2 (en) 2007-08-23 2016-11-15 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8889834B2 (en) 2007-08-23 2014-11-18 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9056915B2 (en) 2007-08-23 2015-06-16 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8981064B2 (en) 2007-08-23 2015-03-17 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9045547B2 (en) 2007-08-23 2015-06-02 Amgen Inc. Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9040052B1 (en) 2013-12-17 2015-05-26 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9034331B1 (en) 2014-07-15 2015-05-19 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9068012B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9109034B1 (en) 2014-07-15 2015-08-18 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9187562B1 (en) 2014-07-15 2015-11-17 Kymab Limited Methods for treating anaemia
US9303089B2 (en) 2014-07-15 2016-04-05 Kymab Limited Methods of treating anaemia
US9394568B2 (en) 2014-07-15 2016-07-19 Kymab Limited Methods of treating anaemia
US9428578B2 (en) 2014-07-15 2016-08-30 Kymab Limited Methods of treating anaemia
US9439963B2 (en) 2014-07-15 2016-09-13 Kymab Limited Methods of treating anaemia
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain

Also Published As

Publication number Publication date
WO2008109871A2 (en) 2008-09-12
WO2008109871A3 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2008109871A3 (en) Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
NO2017029I1 (en) Human antibody that specifically binds human proprotein convertase subtilisin / hexin type 9 (hPCSK9) (alirokumab).
EP1898267A4 (en) Process for production of liquid developer, and liquid developer produced by the process
EP1898268A4 (en) Process for production of liquid developer, and liquid developer produced by the process
CY2016009I2 (en) COMPOUNDS FOR INHIBITING THE PROTEASOME ENZYME
ATE494780T1 (en) 2-CYANOBENZENESULFONAMIDE COMPOUNDS FOR TREATING SEEDS
ZA200709860B (en) The planting of plant material
EP1855863A4 (en) Processes for the production of organometallic compounds
MA31304B1 (en) MOLECULES AND METHODS FOR PROPYTEIN CONVERTASE MODULATION SUBTILISINE / KEXINE TYPE 9 (PCSK9)
MA28985B1 (en) LOXAPINE ANALOGUES AND METHODS OF USE
ATE524200T1 (en) USE OF HYDROPHOBIC BORONATE-GALACTOMANNAN COMPLEXES AS ABSORBENT MATERIAL
ATE448234T1 (en) OLNZAPINE ANALOGUES AND METHODS OF USE THEREOF
DE602008003911D1 (en) CO CRYSTALS OF PROPICONAZOLE
WO2008035066A3 (en) Processes for the preparation of ciclesonide and its crystal form
ZA200607213B (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
ATE540930T1 (en) INDANYL AND TETRAHYDRONAPHTHYLAMINODAZOLINE COMPOUNDS FOR THE CONTROL OF ANIMAL PESTS
WO2006122769A3 (en) Substituted spiro compounds and their use for producing pain-relief drugs
WO2007006591A3 (en) Dihalogenation of n,o-disubstituted hydroxipyridones and uses thereof
NO20065026L (en) Wave field decomposition for cross-line examination
DE502005005756D1 (en) Use of a disk laser for the crystallization of silicon layers
WO2006074464A3 (en) Modulating toll-like receptor activity
WO2008008628A3 (en) Crystal structure of itpk1 and uses thereof
WO2007134262A3 (en) Crystal structure of prostasin and uses thereof
IL191052A0 (en) Process for the preparation of tamsulosin and related compounds
HK1117737A1 (en) Use of adamantyl methoxydi phenyl propenoic acid for the treatment of acne

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08743744

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08743744

Country of ref document: EP

Kind code of ref document: A2